193 related articles for article (PubMed ID: 35307349)
41. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
42. In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity.
Yang WS; Campbell M; Kung HJ; Chang PC
J Vis Exp; 2018 Jan; (131):. PubMed ID: 29443041
[TBL] [Abstract][Full Text] [Related]
43. Sumoylation of a small isoform of NFATc1 is promoted by PIAS proteins and inhibits transactivation activity.
Kim ET; Kwon KM; Lee MK; Park J; Ahn JH
Biochem Biophys Res Commun; 2019 May; 513(1):172-178. PubMed ID: 30952432
[TBL] [Abstract][Full Text] [Related]
44. Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways.
Yang W; Sheng H; Thompson JW; Zhao S; Wang L; Miao P; Liu X; Moseley MA; Paschen W
Stroke; 2014 Apr; 45(4):1115-22. PubMed ID: 24569813
[TBL] [Abstract][Full Text] [Related]
45. SUMO and PIAS repress NF-κB activation in a basal chordate.
Chen S; Fu X; Wang R; Li M; Yan X; Yue Z; Chen SW; Dong M; Xu A; Huang S
Fish Shellfish Immunol; 2023 Jun; 137():108754. PubMed ID: 37088348
[TBL] [Abstract][Full Text] [Related]
46. SUMOylation by the E3 ligase TbSIZ1/PIAS1 positively regulates VSG expression in Trypanosoma brucei.
López-Farfán D; Bart JM; Rojas-Barros DI; Navarro M
PLoS Pathog; 2014 Dec; 10(12):e1004545. PubMed ID: 25474309
[TBL] [Abstract][Full Text] [Related]
47. Regulation of REGγ cellular distribution and function by SUMO modification.
Wu Y; Wang L; Zhou P; Wang G; Zeng Y; Wang Y; Liu J; Zhang B; Liu S; Luo H; Li X
Cell Res; 2011 May; 21(5):807-16. PubMed ID: 21445096
[TBL] [Abstract][Full Text] [Related]
48. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases.
Kotaja N; Karvonen U; Jänne OA; Palvimo JJ
Mol Cell Biol; 2002 Jul; 22(14):5222-34. PubMed ID: 12077349
[TBL] [Abstract][Full Text] [Related]
49. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
[TBL] [Abstract][Full Text] [Related]
50. HIF-1α SUMOylation affects the stability and transcriptional activity of HIF-1α in human lens epithelial cells.
Han X; Wang XL; Li Q; Dong XX; Zhang JS; Yan QC
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1279-90. PubMed ID: 25877955
[TBL] [Abstract][Full Text] [Related]
51. Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility.
Li C; McManus FP; Plutoni C; Pascariu CM; Nelson T; Alberici Delsin LE; Emery G; Thibault P
Nat Commun; 2020 Feb; 11(1):834. PubMed ID: 32047143
[TBL] [Abstract][Full Text] [Related]
52. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.
Morris JR; Boutell C; Keppler M; Densham R; Weekes D; Alamshah A; Butler L; Galanty Y; Pangon L; Kiuchi T; Ng T; Solomon E
Nature; 2009 Dec; 462(7275):886-90. PubMed ID: 20016594
[TBL] [Abstract][Full Text] [Related]
53. Trim39 regulates neuronal apoptosis by acting as a SUMO-targeted E3 ubiquitin-ligase for the transcription factor NFATc3.
Basu-Shrivastava M; Mojsa B; Mora S; Robbins I; Bossis G; Lassot I; Desagher S
Cell Death Differ; 2022 Nov; 29(11):2107-2122. PubMed ID: 35449213
[TBL] [Abstract][Full Text] [Related]
54. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
Mascle XH; Lussier-Price M; Cappadocia L; Estephan P; Raiola L; Omichinski JG; Aubry M
J Biol Chem; 2013 Dec; 288(51):36312-27. PubMed ID: 24174529
[TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of yeast PIAS-type SUMO ligases in vivo and in vitro.
Takahashi Y; Toh-E A; Kikuchi Y
J Biochem; 2003 Apr; 133(4):415-22. PubMed ID: 12761287
[TBL] [Abstract][Full Text] [Related]
56. Chordate PIAS proteins act as conserved repressors of the TRAF6 self-polyubiquitination.
Fu X; Wang R; Li M; Yan X; Huang H; Li J; Chen S; Yue Z; Chen S; Li Y; Dong M; Xu A; Huang S
Dev Comp Immunol; 2020 Mar; 104():103554. PubMed ID: 31758961
[TBL] [Abstract][Full Text] [Related]
57. Biochemical characterization of SUMO-conjugating enzymes by in vitro sumoylation assays.
Eisenhardt N; Ilic D; Nagamalleswari E; Pichler A
Methods Enzymol; 2019; 618():167-185. PubMed ID: 30850051
[TBL] [Abstract][Full Text] [Related]
58. PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.
Chanda A; Ikeuchi Y; Karve K; Sarkar A; Chandhoke AS; Deng L; Bonni A; Bonni S
Cell Death Differ; 2021 Jan; 28(1):267-282. PubMed ID: 32770107
[TBL] [Abstract][Full Text] [Related]
59. The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.
Reuter N; Schilling EM; Scherer M; Müller R; Stamminger T
J Virol; 2017 May; 91(10):. PubMed ID: 28250117
[TBL] [Abstract][Full Text] [Related]
60. SUMOylation of RORalpha potentiates transcriptional activation function.
Hwang EJ; Lee JM; Jeong J; Park JH; Yang Y; Lim JS; Kim JH; Baek SH; Kim KI
Biochem Biophys Res Commun; 2009 Jan; 378(3):513-7. PubMed ID: 19041634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
